Showing articles whose micro-themes are very close to:
#NCPE cost-benefit analysis
- No closely related articles found yet.
- Seanad Éireann Debate on NCPE Cost-Benefit Analysis (oireachtas.ie) | 124d ago
- Rapid Review of Rozanolixizumab (Rystiggo) for gMG Completed by NCPE (ncpe.ie) | 11d ago
- Dostarlimab (Jemperli) – NCPE Rapid Review Recommends Full HTA for Endometrial Cancer (ncpe.ie) | 19d ago
- NCPE Recommends Belzutifan (Welireg) Not Reimbursed for VHL Disease on Cost-Effectiveness Grounds (ncpe.ie) | 39d ago
- NCPE Publishes Updated Budget Impact Model Template v2.3 for Drug Reimbursement Submissions (ncpe.ie) | 57d ago
- Oireachtas Written Answer on Vaccine Cost-Effectiveness for Recombinant Zoster Vaccine (oireachtas.ie) | 17d ago
- HIQA Publishes Health Technology Assessment on Herpes Zoster Vaccine (oireachtas.ie) | 75d ago
- HIQA Commences Health Technology Assessment on COVID-19 Vaccination in Ireland (hiqa.ie) | 35d ago
- HIQA finds insufficient evidence that shingles vaccine prevents dementia (imt.ie) | 17d ago
Showing page 1 of 1
(9 total results)
← Prev
Next →